Schonfeld Strategic Advisors LLC Arbutus Biopharma Corp Transaction History

Schonfeld Strategic Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.88 - $2.88 $59,972 - $91,872	31,900 New	31,900 $61,000
Q1 2022 May 16, 2022	SELL	$2.42 - $3.98 $30,250 - $49,750	-12,500 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$3.11 - $4.61 $414,563 - $614,513	-133,300 Reduced 91.43%	12,500 $49,000
Q3 2021 Nov 16, 2021	BUY	$2.65 - $4.62 $386,370 - $673,596	145,800 New	145,800 $626,000
Q2 2021 Aug 16, 2021	SELL	$2.5 - $3.51 $31,797 - $44,643	-12,719 Closed	0 $0

Q1 2021 May 17, 2021	BUY	$3.14 - $4.84 $39,937 - $61,559	12,719 New	12,719 $42,000
Q4 2017 Feb 14, 2018	SELL	$4.45 - $7.7 $556,250 - $962,500	-125,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$3.4 - $7.0 $425,000 - $875,000	125,000	125,000 $775,000

130

82.2M

4.82M

546K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $468M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.